• Sionna Therapeutics posted a wider net loss of $26.8 million for first quarter ended March 31, 2026, compared with a net loss of $16.5 million a year earlier.
• R&D expenses climbed to $19 million from $13.7 million, due mainly to development spending to advance clinical pipeline plus higher personnel-related costs including stock-based compensation.
• G&A costs rose to $10.6 million from $6 million, primarily on higher personnel-related expenses including stock-based compensation.
• Cash, cash equivalents, marketable securities totaled $289.9 million; company expects that balance to fund operations into 2028.
• Enrollment completed in PreciSION CF Phase 2a trial of SION-719 with topline data expected in summer 2026; Phase 1 dual-combination study of SION-451 with SION-2222 and SION-109 also targets a summer 2026 topline readout.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sionna Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-033870), on May 12, 2026, and is solely responsible for the information contained therein.